NEWS HIGHLIGHTS
Published Studies Related to Avapro (Irbesartan)
Irbesartan improves arterial compliance more than lisinopril. [2009]
BACKGROUND: Antihypertensive agents can reduce arterial stiffness. We hypothesized that an angiotensin receptor blocker (ARB) irbesartan and an angiotensin converting enzyme inhibitor (ACEI) lisinopril improved arterial compliance... CONCLUSIONS: Irbesartan improved arterial compliance in elastic and muscular arteries, whereas lisinopril improved it only in elastic arteries.
Irbesartan in patients with heart failure and preserved ejection fraction. [2008.12.04]
BACKGROUND: Approximately 50% of patients with heart failure have a left ventricular ejection fraction of at least 45%, but no therapies have been shown to improve the outcome of these patients. Therefore, we studied the effects of irbesartan in patients with this syndrome... CONCLUSIONS: Irbesartan did not improve the outcomes of patients with heart failure and a preserved left ventricular ejection fraction. (ClinicalTrials.gov number, NCT00095238.) 2008 Massachusetts Medical Society
A Randomized Trial of the Effect of an Angiotensin II Receptor Blocker SR47436 (Irbesartan) on 24-Hour Blood Pressure in Patients with Essential Hypertension. [2008.09]
The aim of this placebo-controlled, double-blind randomized study was to evaluate the duration of the effect of once-daily administration of irbesartan in patients with essential hypertension. After a placebo run-in baseline period (of 2-4 weeks), 79 patients were randomized to either irbesartan (one 100 mg tablet per day) or placebo, for 6 weeks.
The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial. [2008.07]
BACKGROUND: The aim of this study was to investigate the effect of the plasma concentration of irbesartan, a specific angiotensin II type 1 receptor (AT1R) antagonist, and the blood pressure response in relation to AT1R gene polymorphisms... CONCLUSIONS: There was an association between plasma concentrations of irbesartan and the blood pressure response for hypertensive patients with AT1R 5245 TT. Because of the small sample size, this study needs to be viewed as hypothesis generating. This is the first study, to our knowledge, indicating that the concentration-response relationship of an antihypertensive drug may be genotype dependent.
Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study. [2008.05]
OBJECTIVES: Angiotensin II receptor antagonists have been shown to moderately lower portal pressure in some patients with cirrhosis but may have adverse effects on kidney function. This study aimed at comparing the effects of a combined treatment using irbesartan plus propranolol with propranolol monotherapy on portal pressure and kidney function in patients with cirrhosis... CONCLUSIONS: Combination treatment of propranolol plus irbesartan is well tolerated in cirrhotic patients when titrating the angiotensin II antagonist in a step-up manner, and it increases sodium excretion in patients with compensated or moderately decompensated cirrhosis. Addition of irbesartan has no effect on portal pressure.
Clinical Trials Related to Avapro (Irbesartan)
Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension [Completed]
Study Objectives :
- To demonstrate the reduction in office Blood Pressure following a 8-week regimen of
irbesartan / hydrochlorothiazide using irbesartan as a reference.
- To demonstrate the reduction in office Blood Pressure after 4-week regimen of irbesartan
/ hydrochlorothiazide using irbesartan as a reference.
- To compare the response rate (defined as office Systolic Blood Pressure/Diastolic Blood
Pressure reduce more than 10mmHg from Week 0) of patients after 4-week and 8-week
regimen of irbesartan / hydrochlorothiazide versus irbesartan.
- To compare the proportion of patients requiring titration after 4-week regimen of
irbesartan/hydrochlorothiazide versus irbesartan
- To ascertain the safety and tolerability of irbesartan / hydrochlorothiazide versus
irbesartan when administered once daily
Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel� (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice [Completed]
Primary:
- To evaluate the efficacy of two regimens of irbesartan in patients responding but not
normalized at 6 weeks of treatment (schema N°1: maintenance 150 mg/day, schema n°2: 300
mg/day for 6 more weeks)
Secondary:
- To evaluate the percentage of patients with DBP < 90 mmHg at 6 and 12 weeks
- To evaluate the percentage of patients with SBP < 140 mmHg at 6 and 12 weeks
- To evaluate rate of adverse events during the study
Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF) [Completed]
The main purpose of the study is to compare the mean AERP between treatment groups based on
the hypothesis that in subjects with paroxysmal AF, Irbesartan prevents electrophysiological
remodeling resulting in a prolonged atrial effective refractory period relative (AERP) to
placebo.
Irbesartan/Hydrochlorothiazide National Taiwan University Hospital Listing [Active, not recruiting]
Primary:
1. To compare the change in forearm vascular resistance following a 12-week regimen of
irbesartan/hydrochlorothiazide versus irbesartan
2. To assess changes of serum proinflammatory cytokine, markers of cardiovascular risks,
oxidative stress and circulating adhesion molecule including thiobarbiturate acid
reactive substances (TBARS), C-reactive protein (CRP), interleukin 6 (IL-6), and
vascular cell adhesion molecule 1 (VCAM-1).
Secondary:
1. To compare the reduction in office blood pressure following a 12-week regimen of
irbesartan/hydrochlorothiazide versus irbesartan
2. To compare the response rate (defined as office Systolic blood pressure(SBP)/diastolic
blood pressure (DBP) reduce more than 10mmHg from baseline), and BP controlled rate
(defined as SBP<140 mmHg and /or DBP<90 mmHg)
3. To ascertain the safety and tolerability of irbesartan / hydrochlorothiazide versus
irbesartan when administered once daily
4. To determine whether angiotensin II type 1 (AT-1) receptor gene polymorphisms (including
A1166C gene with about 4% of the minor allele frequency in Chinese population and other
single nucleotide polymorphisms with a higher frequency of about 10% of minor allele) is
related to reduction of BP
Irbesartan in Hypertension [Completed]
Study objectives:
- To demonstrate the effect of irbesartan on the regulation of diastolic blood pressure,
in case of missing one dose after a period of administration for 6 to 8 weeks
- To evaluate the safety of irbesartan
|
